Table 2 Changes of urinary deoxypyridinoline excretion during denosumab treatment
From: Two years’ experience with denosumab for children with Osteogenesis imperfecta type VI
Urinary deoxypyridinoline/creatinine ratio (age related normal range) | ||||
|---|---|---|---|---|
Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
Days after injection | 1 st Cycle | 1 st Cycle | 1 st Cycle | 1 st Cycle |
Day 1 | 44 (6.5-26.5 nM/mM) | 32 (6.5-26.5 nM/mM) | 82 (6.5-26.5 nM/mM) | 41 (0.0-17.8 nM/mM) |
Day 14 | 14 (6.5-26.5 nM/mM) | 25 (6.5-26.5 nM/mM) | 26 (6.5-26.5 nM/mM) | 20 (0.0-17.8 nM/mM) |
Day 28 | 25 (6.5-26.5 nM/mM) | 13 (6.5-26.5 nM/mM) | 25 (6.5-26.5 nM/mM) | 17 (0.0-17.8 nM/mM) |
3 rd Cycle | 4 th Cycle | 8 th Cycle | 8 th Cycle | |
Day 1 | 48 (6.5-26.5 nM/mM) | 78 (6.5-26.5 nM/mM) | 620 (110–450 μg/g) | 83 (10–50 μg/g) |
Day 14 | 10 (6.5-26.5 nM/mM) | 24 (6.5-26.5 nM/mM) | 133 (110–450 μg/g) | 50 (10–50 μg/g) |
Day 28 | 32 (6.5-26.5 nM/mM) | 19 (6.5-26.5 nM/mM) | 431* (110–450 μg/g) | 23 (10–50 μg/g) |
7 th Cycle | 10 th Cycle | - | - | |
Day 1 | 42 (6.5-26.5 nM/mM) | 477 (110–450 μg/g) | - | - |
Day 14 | 28 (6.5-26.5 nM/mM) | 110 (110–450 μg/g) | - | - |
Day 28 | 19 (6.5-26.5 nM/mM) | 197 (110–450 μg/g) | - | - |